Stem Cell Clinic

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

By Stem Cell Doctors

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that it will participate in Citi’s 2024 Global Healthcare Conference. Members of the Y-mAbs management team will host one-on-one meetings at the conference on Wednesday, December 4, 2024 in Miami, FL.

Read the original:
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

By Stem Cell Doctors

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.

Read the rest here:
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

By Stem Cell Doctors

ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY on Wednesday, December 4, 2024 at 11:30 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, December 4, 2024.

View original post here:
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Radiopharm Achieves Nasdaq Listing of American Depositary Shares

By Stem Cell Doctors

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that American Depositary Shares (“ADSs”) representing its ordinary shares will commence trading on the Nasdaq Capital Market (“Nasdaq”) on Wednesday morning, 27 November 2024 US time, under the ticker symbol “RADX”. Each ADS represents 300 ordinary shares of the Company.

See the original post:
Radiopharm Achieves Nasdaq Listing of American Depositary Shares

Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

By Stem Cell Doctors

CLEARWATER, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, in New York, NY.

Read the original post:
Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

By Stem Cell Doctors

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, today announced the Australian Patent Office has formally granted Recce a family three patent for its anti-infectives, with expiry in 2037.

Read the original:
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

By Stem Cell Doctors

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.

Continue reading here:
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

By Stem Cell Doctors

BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global

View post:
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

By Stem Cell Doctors

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.

Read the original:
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

By Stem Cell Doctors

Lyon (France) – November 27, 2024, at 02:30 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, presented an ambitious development strategy to take advantage of the rapidly evolving phage therapy area.

Go here to read the rest:
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

→←